▲ Peaking
Business
Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial
5sources
5articles
3velocity
+124%since first seen
2h agofirst detected
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Coverage (5)
- Can Pfizer (NYSE:PFE) Clear Its Latest Oncology Hurdle? Kalkine Media · 8h ago
- Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial CancerNetwork · 8h ago
- Pfizer drug acquired in Seagen deal disappoints in lung cancer study BioPharma Dive · 8h ago
- Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC OncLive · 8h ago
- Pfizer's $43B Seagen bet sours further as ADC fails in late-stage lung cancer trial Endpoints News · 8h ago
Related trends
▲ Peaking
Business
Meta Has Created a Prediction Markets App
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
▲ Peaking
Business
IonQ, Infleqtion Buck Tech’s Selloff. Trump Love Sparks a Rally.
▲ Peaking
Business
Anthropic’s Claude Tag is learning your company, one Slack message at a time
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
▲ Peaking
Business
Exclusive | Walmart, in Biggest Deal in Two Years, Buys Advertising Tech Firm
↑ Rising
Business
Meet the Starbucks Pink Bearista Glass Cold Cups: a Pink Drink-inspired collectible coming in July
↓ Cooling
Business